Skip to main
  1. Stocks
  2. PACS Group, Inc.
  3. Forecast
PACS

PACS Stock Forecast & Price Target

PACS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PACS Group is benefiting from strong same-store execution, with 3Q26 SNF revenue up 6.4%, occupancy rising to 91.3%, and skilled mix improving to 29.5%, which helped drive revenue of $1.499 billion and adjusted EBITDA of $175.7 million. Its outlook is reinforced by expansion momentum, as the company has added more than 8K net beds, raised 2026 adjusted EBITDA guidance to $685 million-$695 million, and generated $211.2 million of CFFO and $178.7 million of FCF in 3Q26. Financial flexibility remains a major strength, supported by $707.4 million of liquidity, net leverage of just 0.2x, quality-linked payments, and improving controls expected to be fully remediated by year-end 2026.

Bears say

PACS Group is exposed to meaningful reimbursement and policy risk, as potential Medicaid funding reforms and the rising penetration of Medicare Advantage could pressure skilled nursing margins, reduce clinical staffing capacity, and lower reimbursement versus Medicare fee-for-service. Its heavy concentration in California adds geographic risk, since the state’s structurally higher occupancy and skilled mix can distort future KPI comparisons as the company expands beyond it. Although weaker industry margins could spur M&A, that upside may reflect distress among smaller operators rather than durable organic growth for PACS.

PACS has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PACS Group, Inc. and is not a guaranteed prediction by Public.com or investment advice.

PACS Analyst Forecast & Price Prediction

Get the latest PACS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PACS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PACS Group, Inc. (PACS) Forecast

Analysts have given PACS a Buy based on their latest research and market trends.

According to 6 analysts, PACS has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PACS Group, Inc. (PACS)


PACS Analyst Forecast & Price Prediction

Get the latest PACS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PACS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PACS stock data and trends